NRICM101 potentially affected the inflammatory cytokine signaling, including TNFR2, TNFR1, IL-1, IL-2, IL-4, IL-6, IL-7, IL-12, IL-13, IL-17, and IL-23 Signaling (Fig. 3), all of which were previously identified in COVID-19 [46,47]. This evidence concerns the gene IL17A and COVID-19.